MAI Capital Management grew its stake in shares of Allergan plc (NYSE:AGN) by 3.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,465 shares of the company’s stock after acquiring an additional 448 shares during the quarter. MAI Capital Management’s holdings in Allergan were worth $2,946,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gradient Investments LLC boosted its holdings in shares of Allergan by 747.5% during the 3rd quarter. Gradient Investments LLC now owns 678 shares of the company’s stock valued at $129,000 after acquiring an additional 598 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Allergan during the 2nd quarter valued at about $129,000. Kaizen Advisory LLC boosted its holdings in shares of Allergan by 156.2% during the 2nd quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock valued at $138,000 after acquiring an additional 506 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Allergan by 3,193.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock valued at $165,000 after acquiring an additional 958 shares during the last quarter. Finally, Aries Wealth Management purchased a new stake in shares of Allergan during the 2nd quarter valued at about $202,000. 77.38% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Joseph H. Boccuzi bought 900 shares of the firm’s stock in a transaction on Thursday, August 30th. The shares were bought at an average price of $190.59 per share, for a total transaction of $171,531.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction on Thursday, September 6th. The shares were purchased at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.37% of the stock is currently owned by company insiders.

A number of brokerages have recently issued reports on AGN. Zacks Investment Research downgraded shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a report on Friday, September 21st. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Cantor Fitzgerald reissued a “hold” rating and issued a $180.00 price objective on shares of Allergan in a report on Friday, September 14th. Finally, Wells Fargo & Co set a $232.00 price objective on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday, August 22nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $211.91.

NYSE AGN opened at $183.28 on Friday. Allergan plc has a 12 month low of $142.81 and a 12 month high of $207.24. The company has a market cap of $64.66 billion, a price-to-earnings ratio of 11.21, a PEG ratio of 1.47 and a beta of 1.19. The company has a current ratio of 1.00, a quick ratio of 0.85 and a debt-to-equity ratio of 0.34.

Allergan (NYSE:AGN) last released its earnings results on Thursday, July 26th. The company reported $4.42 EPS for the quarter, topping analysts’ consensus estimates of $4.13 by $0.29. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter last year, the business earned $4.02 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. As a group, analysts expect that Allergan plc will post 16.29 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, September 17th. Shareholders of record on Friday, August 17th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.57%. The ex-dividend date of this dividend was Thursday, August 16th. Allergan’s payout ratio is 17.61%.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

See Also: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.